David Shoultz

Affiliate Associate Professor, Epidemiology



MBA Seattle University, 2012
PhD Epidemiology, University of Washington, 1997
MS Epidemiology, University of Washington, 1995
BSN University of Washington, 1991



Monod Bio, Inc.
700 Dexter Avenue N, Suite 700
Seattle, WA 98109


Dr. David Shoultz is the Chief Operating Officer and Co-Founder of Monod Bio, Inc. Monod Bio is a biotechnology company focused on creating new clinical diagnostics and laboratory tools based on its de novo protein design platform for biosensors.  The Company is a spin-out from the lab of Dr. David Baker at the University of Washington Institute for Protein Design (IPD).

Prior to launching Monod Bio with his co-founders Drs. Daniel Silva Manzano and Alfredo Quijano Rubio, David held multiple positions of increasing responsibility at biotech, pharmaceutical, and life sciences companies.  In addition, he held significant leadership positions in global health product development at the Bill & Melinda Gates Foundation and PATH.  At PATH, David was the Global Program Leader for the Drug Development Program.

David received his bachelor’s degree, M.S., and Ph.D. from the University of Washington in Seattle. His MBA is from the Albers School of Business & Economics at Seattle University, where he is a faculty member in the Executive MBA Program. He has been on the Affiliate Faculty at the University of Washington in the departments of Epidemiology and Global Health for more than twenty (20) years, has advised students, given guest lectures, and designed and taught courses on global health.  In addition, he was a member of the faculty at the Seattle University School of Business & Economics for many years; there he advised students and taught courses on strategy, operations, and global health.

David's expertise includes the development of diagnostics, drugs, and vaccines.  He has been very successful raising venture capital for various enterprises and serves as an advisor to private equity firms. His work has convinced him of the critical role that the private sector plays in public health, poverty alleviation, and innovation. He has a special interest in infectious diseases.

Research Interests

I am interested in global health product discovery, development, and delivery. I am also interested in innovative finance for global health product development. I am eager to collaborate with other faculty members and am available to work with master’s and doctoral students who share my interests and commitment to global health product development.

Recent Publications (PubMed)

De Novo Human Angiotensin-Converting Enzyme 2 Decoy NL-CVX1 Protects Mice From Severe Disease After Severe Acute Respiratory Syndrome Coronavirus 2 Infection.
(2023 Sep 15)
J Infect Dis 228(6): 723-733
Rebelo M, Tang C, Coelho AR, Lab√£o-Almeida C, Schneider MM, Tatalick L, Ruivo P, de Miranda MP, Gomes A, Carvalho T, Walker MJ, Ausserwoeger H, Pedro Simas J, Veldhoen M, Knowles TPJ, Silva DA, Shoultz D, Bernardes GJL

Morbidity and mortality due to shigella and enterotoxigenic Escherichia coli diarrhoea: the Global Burden of Disease Study 1990-2016.
(2018 Nov)
Lancet Infect Dis 18(11): 1229-1240
Khalil IA, Troeger C, Blacker BF, Rao PC, Brown A, Atherly DE, Brewer TG, Engmann CM, Houpt ER, Kang G, Kotloff KL, Levine MM, Luby SP, MacLennan CA, Pan WK, Pavlinac PB, Platts-Mills JA, Qadri F, Riddle MS, Ryan ET, Shoultz DA, Steele AD, Walson JL, Sanders JW, Mokdad AH, Murray CJL, Hay SI, Reiner RC Jr

Morbidity, mortality, and long-term consequences associated with diarrhoea from Cryptosporidium infection in children younger than 5 years: a meta-analyses study.
(2018 Jul)
Lancet Glob Health 6(7): e758-e768
Khalil IA, Troeger C, Rao PC, Blacker BF, Brown A, Brewer TG, Colombara DV, De Hostos EL, Engmann C, Guerrant RL, Haque R, Houpt ER, Kang G, Korpe PS, Kotloff KL, Lima AAM, Petri WA Jr, Platts-Mills JA, Shoultz DA, Forouzanfar MH, Hay SI, Reiner RC Jr, Mokdad AH

Pediatric cryptosporidiosis: An evaluation of health care and societal costs in Peru, Bangladesh and Kenya.
PLoS One 12(8): e0182820
Rafferty ER, Schurer JM, Arndt MB, Choy RKM, de Hostos EL, Shoultz D, Farag M

Addressing Cryptosporidium Infection among Young Children in Low-Income Settings: The Crucial Role of New and Existing Drugs for Reducing Morbidity and Mortality.
(2016 Jan)
PLoS Negl Trop Dis 10(1): e0004242
Shoultz DA, de Hostos EL, Choy RK

Show complete publication list